CLOs on the Move

BioXcel Therapeutics

www.bioxceltherapeutics.com

 
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company`s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company`s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Javier Rodriguez
 Senior Vice President, Chief Legal Officer, and Corporate Secretary Profile

Similar Companies

Medical Technology Systems

Medical Technology Systems, Inc. is a Saint Petersburg, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Bridgeway

Bridgeway provides services for individuals with developmental disabilites, families

SinusPharmaceuticals

SinusPharmaceuticals is a Carpinteria, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medac Corporation

Medac Corporation is a Augusta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cyteir

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.